Unleashing the power of p53: Lessons from mice and men

Genes and Development

Volumn 20, Issue 2, 2006, Pages 125-131

  Poyurovsky, Masha V ^a   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; RITA; UNCLASSIFIED DRUG;

AGING; ALLELE; APOPTOSIS; CARCINOGENESIS; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STATISTICAL SIGNIFICANCE; WILD TYPE;

AGING, PREMATURE; ANIMALS; CELL DEATH; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MODELS, GENETIC; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 30944435091     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1397506     Document Type: Review

References (56)

1. Arkin, M.R. and Wells, J.A. 2004. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discov. 3: 301-317.
2. Arva, N.C., Gopen, T.R., Talbott, K.E., Campbell, L.E., Chicas, A., White, D.E., Bond, G.L., Levine, A.J., and Bargonetti, J. 2005. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 280: 26776-26787.
3. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K., and Vogelstein, B. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
4. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
5. Bottger, V., Bottger, A., Howard, S.F., Picksley, S.M., Chene, P., Garcia-Echeverria, C., Hochkeppel, H.K., and Lane, D.P. 1996. Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141-2417.
6. Bottger, A., Bottger, V., Sparks, A., Liu, W.L., Howard, S.F., and Lane, D.P. 1997. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7: 860-869.
7. Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K., and Lane, D.P. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes & Dev. 19: 2122-2137.
8. Campisi, J. 2005. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120: 513-522.
9. Chen, L., Gilkes, D.M., Pan, Y., Lane, W.S., and Chen, J. 2005. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24: 3411-3422.
10. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M.R., Pollack, D., Woodruff, J.M., Marechal, V., Chen, J., Brennan, M.F., and Levine, A.J. 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794-799.
11. Courtois, S., Verhaegh, G., North, S., Luciani, M.G., Lassus, P., Hibner, U., Oren, M., and Hainaut, P. 2002. ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21: 6722-6728.
12. D'Orazi, G., Marchetti, A., Crescenzi, M., Coen, S., Sacchi, A., and Soddu, S. 2000. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: Implications for cancer gene therapy without tumor targeting. J. Gene Med. 2: 11-21.
13. Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G.D., Dowd, P., O'Rourke, K., Koeppen, H., and Dixit, V.M. 2004. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
14. Duncan, S.J., Gruschow, S., Williams, D.H., McNicholas, C., Purewal, R., Hajek, M., Gerlitz, M., Martin, S., Wrigley, S.K., and Moore, M. 2001. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123: 554-560.
15. Duncan, S.J., Cooper, M.A., and Williams, D.H. 2003. Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem. Commun. (Camb.) 316-317.
16. Fasan, R., Dias, R.L., Moehle, K., Zerbe, O., Vrijbloed, J.W., Obrecht, D., and Robinson, J.A. 2004. Using a β-hairpin to mimic an α-helix: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem. Int. Ed. Engl. 43: 2109-2112.
17. Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado, L.M., Klatt, P., Flores, J.M., Weill, J.C., Blasco, M.A., and Serrano, M. 2002. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21: 6225-6235.
18. Garcia-Echeverria, C., Chene, P, Blommers, M.J., and Furet, P. 2000. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43: 3205-3208.
19. Gentry, A. and Venkatachalam, S. 2005. Complicating the role of p53 in aging. Aging Cell 4: 157-160.
20. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L.G., Masucci, M., Pramanik, A., and Selivanova, G. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10: 1321-1328.
21. Iwakuma, T. and Lozano, G. 2003. MDM2, an introduction. Mol. Cancer Res. 1: 993-1000.
22. Jones, S.N., Roe, A.E., Donehower, L.A., and Bradley, A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
23. Jones, S.N., Hancock, A.R., Vogel, H., Donehower, L.A., and Bradley, A. 1998. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. 95: 15608-15612.
24. Kumar, S.K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N.E., and Khan, S.R. 2003. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem. 46: 2813-2815.
25. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J., and Pavletich, N.P. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
26. Lai, Z., Yang, T., Kim, Y.B., Sielecki, T.M., Diamond, M.A., Strack, P., Rolfe, M., Caligiuri, M., Benfield, P.A., Auger, K.R., et al. 2002. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. 99: 14734-14739.
27. Leng, R.P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J.M., Lozano, G., Hakem, R., and Benchimol, S. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
28. Lundgren, K., Montes de Oca Luna, R., McNeill, Y.B., Emerick, E.P., Spencer, B., Barfield, C.R., Lozano, G., Rosenberg, M.P., and Finlay, C.A. 1997. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes & Dev. 11: 714-725.
29. Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., and Scrable, H. 2004. Modulation of mammalian life span by the short isoform of p53. Genes & Dev. 18: 306-319.
30. Marine, J.C. and Jochemsen, A.G. 2005. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331: 750-760.
31. Mendrysa, S.M., McElwee, M.K., Michalowski, J., O'Leary, K.A., Young, K.M., and Perry, M.E. 2003. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23: 462-472.
32. Mendrysa, S.M., O'Leary, K.A., McElwee, M.K., Michalowski, J., Eisenman, R.N., Powell, D.A., and Perry, M.E. 2006. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes & Dev. 20: 16-21.
33. Migliorini, D., Denchi, E.L., Danovi, D., AJochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P.G., and Marine, J.C. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22: 5527-5538.
34. Mills, A.A. 2005. p53: Link to the past, bridge to the future. Genes & Dev. 19: 2091-2099.
35. Moll, U.M. and Zaika, A. 2000. Disrupting the p53-mdm2 interaction as a potential therapeutic modality. Drug Resist. Updat. 3: 217-221.
36. Momand, J., Wu, H.H., and Dasgupta, G. 2000. MDM2 - Master regulator of the p53 tumor suppressor protein. Gene 242: 15-29.
37. Montes de Oca Luna, R., Wagner, D.S., and Lozano, G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
38. Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.C., et al. 2005. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 25: 9608-9620.
39. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
40. Onel, K. and Cordon-Cardo, C. 2004. MDM2 and prognosis. Mol. Cancer Res. 2: 1-8.
41. Parant, J., Chavez-Reyes, A., Little, N.A., Yan, W., Reinke, V., Jochemsen, A.G., and Lozano, G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29: 92-95.
42. Pereg, Y., Shkedy, D., de Graaf, P., Meulmeester, E., delson-Averbukh, M., Salek, M., Biton, S., Teunisse, A.F., Lehmann, W.D., Jochemsen, A.G., et al. 2005. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. 102: 5056-5061.
43. Poyurovsky, M.V., Jacq, X., Ma, C., Karni-Schmidt, O., Parker, P.J., Chalfie, M., Manley, J.L., and Prives, C. 2003. Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol. Cell 12: 875-887.
44. Prives, C. and Hall, P.A. 1999. The p53 pathway. J. Pathol. 187: 112-126.
45. Prives, C. and Manfredi, J.J. 2005. The continuing saga of p53 - More sleepless nights ahead. Mol. Cell 19: 719-721.
46. Rohaly, G., Chemnitz, J., Dehde, S., Nunez, A.M., Heukeshoven, J., Deppert, W., and Dornreiter, I. 2005. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122: 21-32.
47. Schon, O., Friedler, A., Freund, S., and Fersht, A.R. 2004. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J. Mol. Biol. 336: 197-202.
48. Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Muhlhahn, P., et al. 2001. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40: 336-344.
49. Thompson, T., Tovar, C., Yang, H., Carvajal, D., Vu, B.T., Xu, Q., Wahl, G.M., Heimbrook, D.C., and Vassilev, L.T. 2004. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279: 53015-53022.
50. Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53.
51. Vassilev, L.T. 2004. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics. Cell Cycle 3: 419-421.
52. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
53. Vousden, K.H. and Lu, X. 2002. Live or let die: The cell's response to p53. Nat. Rev. Cancer 2: 594-604.
54. Vousden, K.H. and Prives, C. 2005. p53 and prognosis: New insights and further complexity. Cell 120: 7-10.
55. Yang, Y., Ludwig, R.L., Jensen, J.P., Pierre, S.A., Medaglia, M.V., Davydov, I.V., Safiran, Y.J., Oberoi, P., Kenten, J.H., Phillips, A.C., Weissman, A.M., and Vousden, K.H. 2005. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559.
56. Yin, Y., Stephen, C.W., Luciani, M.G., and Fahraeus, R. 2002. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 4: 462-467.